This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The National Organization for the Reform of Marijuana Laws (NORML) has formally submitted comments to the US Federal Register opposing the Drug Enforcement Administration’s proposed rule changes governing the federal production and distribution of cannabis for clinical research purposes.
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada.
We look forward to his expertise as we expand our mental health analytical platform and enter clinicaltrials. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Ehave, Inc.
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. Los Angeles, California. www.InvestorBrandNetwork.com. 310.299.1717 Office.
… Without access to an expanded range of cannabis products engineered under FDA-approved Good Manufacturing Practices, scientific research cannot hope to keep pace with the ever expanding recreational and medicinal cannabis marketplace.” ” The APA represents nearly 120,000 researchers and clinicians. .”
There is an urgent need for objective, scientifically sound and robust clinicaltrials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). Collectively, between the two organizations we offer a full-service package from protocol development to timely and successful clinicaltrial execution.”.
Virtual ClinicalTrials transcend geographic, mobility and economic barriers. Clinicaltrials are medical research projects involving human participants. However, the costs of conducting a full-scale clinicaltrial can be prohibitive, posing barriers to research for cannabis companies.
This week, the suing parties filed an Opening Brief in the Ninth Circuit Court of Appeals arguing that under the state and federal Right to Try Act seriously ill patients have a right to use medicines that are currently undergoing clinicaltrials, such as psilocybin (the active compound in magic mushrooms) and MDMA. Read more .
House lawmakers introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinicaltrials involving cannabis. At the state level, patients in Ohio and Oklahoma now have access to medical cannabis, as sales began in both states this week. Additionally, a bipartisan coalition of U.S.
Researchers studying the efficacy of marijuana treatments for veterans’ mental health now have access to $20 million in marijuana tax revenue to fund clinicaltrials. None of it was initially slated to go to clinicaltrials. The deadline for proposals is Friday, July 16. Read more at.
Steve Cohen (D-TN) and Don Young (R-AK) re-introduced the Compassionate Access, Research Expansion and Respect States (CARERS) Act, which protects those engaged in state-lawful medical marijuana programs from federal prosecution. Legislation is pending, HB 350, to expand medical cannabis access. MA resident? New Hampshire.
The results of our successful pivotal Phase 3 clinicaltrial were recently published in Nature Medicine and profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable, and accessible work environment. European Regulatory Lead Executive Summary. Key Responsibilities.
The state of the law on psychedelic substances is in flux. Some of the most promising substances, and the law applicable to each, are outlined below: Psilocybin. As such, the use, sale, and possession of psilocybin in the United States is illegal under federal law. have also passed “Right to Try” laws.
Thus, providing a new pathway for patients to access psychedelic treatment, and another example of the medicinal approach to psychedelic legalization. Each request is decided on a patient-by-patient basis and approval is usually only given to drugs with successful phase II or phase II clinicaltrials.
The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable ClinicalTrials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinicaltrials in the areas of psychedelics and nutraceuticals, among other substances of study.
Senate Bill 253: The Cannabidiol and Marihuana Research Expansion Act provides the office of US Attorney General, rather than the US Drug Enforcement Administration, the discretion to license scientists to engage in clinicaltrials involving the use of cannabis by human subjects.
AMC will use the products in clinicaltrials as well as help ‘seek US regulatory approvals for all products which they intend to distribute’. Co-founder and Managing Director of MGC Pharma Roby Zomer believes this is a turning point for the company, allowing it to access one of the largest healthcare markets in the world.
Key Transaction Details: The Valens Company, a leading Canadian manufacturer of cannabis products, has entered into a long-term partnership with Epsilon, for exclusive access to the Epsilon’s GMP Manufacturing Facility in Southport , Queensland Australia (the “ Southport Facility ‘).
Completion of acquisition provides Creso Pharma with access to the emerging global market for psychedelic medicines – estimated to be worth up to US100Bni. ? Halucenex to progress phase II clinicaltrial to test the efficacy of psilocybin when used to treat Post Traumatic Stress Disorder (PTSD). ? Highlights: ?
As psychedelic therapy trials approach FDA approval, researchers express the urgent need to ensure effectiveness and accessibility to communities of color. Madison Natarajan, MS. – August 5, 2021.
The agency in 2016 first announced its intent to license private entities to grow cannabis for FDA-approved clinicaltrials. However, most of those applications have been before DEA for several years, and the agency still has yet to provide any explicit timeline regarding when, if ever it intends to act on them.
THE Member of Parliament sponsoring the Medical Cannabis Access Bill in the House of Commons today has acknowledged it is set to fail due to lack of political support. Cannabis Trials. BusinessCann UK reports that the UK Medical Cannabis Bill has Buckley’s chance.
The Project on Psychedelics Law and Regulation (POPLAR). The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School is engaged in a three-year initiative to examine the ethical, legal, and social implications of psychedelics research, commerce, and therapeutics. Background. The Project.
Wednesday, Representative Michael Davis, R-Kansas City, proposed legislation that would modify Missouri’s existing ‘Right-to-Try’ law. Right-to-try permits those patients to have access to investigational drugs. Right-to-try permits those patients to have access to investigational drugs.
Instead, it essentially makes arrests for psilocybin the lowest priority for law enforcement. While decriminalization decreases the negative impact of legal issues, it does not provide accessible, safe, and regulated psilocybin for those seeking treatment. Decriminalized Decriminalization does not mean psilocybin is legal.
This exciting partnership between these innovative startups aims to advance patient access to psychedelic treatments in Europe, and improve the quality of the psychedelic medicines produced in Europe. We look forward to working closely with the Clerkenwell Health team to advance our psychedelic drug programs through clinicaltrials.”.
In clinicaltrials, psilocybin (the psychoactive substance in mushrooms) has shown tremendous promise in treating severe depression, post-traumatic stress disorder, and other mental illnesses. The War on Drugs is a failure and continuing to focus law enforcement resources on people using cannabis and psilocybin doesn’t make sense.
This is Numinus’ first psilocybin-assisted therapy treatment outside of ongoing clinicaltrials, and among the first to use of this regulatory mechanism through Health Canada’s Special Access Program (“SAP”), which was amended January 5 th , 2022 to include access to psychedelic compounds on a case-by-case basis.
When the law changed in the UK in 2018, I was humbled by the efforts of those who suffer on a daily basis to achieve legal access to medicinal cannabis. These qualities are necessary to ensure that the private medical cannabis space conducts itself with compassion and respect for those who are accessing medication through it.
Legal cannabis partnership to help patient access. The new distributor in the Australian medicinal cannabis industry – The Entourage Effect – has signed a firstof its kind deal with innovative medical cannabis clinic MiDispensary. UPDATED : Wednesday 12th of January 2022. SYDNEY, AUSTRALIA –.
In order to legally access other therapies including nature-based options such as psilocybin , you must gain access under a Right to Try law which requires you to have a terminal condition. Today there are 41 states that have enacted some form of a Right to Try or RTT laws. A Push by Patients.
ETF, investors also have much easier access to the market. Filament Health partnered with TrPR Psychedelic Research Program at UCSF to advance drug candidates through clinicaltrials. The PsyIndex moved marginally higher last week as new companies continue to announce plans to go public. With the recent launch of the first U.S.
Some exceptions have been made to allow the use of certain psychedelics in religious ceremonies, and some states and municipalities have deprioritized enforcement of laws prohibiting possession of plant and fungi-derived substances (see below). But these substances remain illegal under federal law. Where Laws Are Changing.
11, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2021 and gave an update on recent progress across its business. LONDON, Aug. Business highlights.
In Attorney , Federal Law , Kathryn Tucker , Oregon , Psychedelics. A multitude of recent clinicaltrials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Access Pursuant to the Oregon Psilocybin Services Act. September 30, 2021. Kathryn Tucker.
Patient access. I’ve been working hard with some great advocates for patient access in the UK and this position will give me the opportunity to ensure that patients will have access to the high-quality medicines and products they deserve.”.
This includes First Time in Human (“FTiH”) clinicaltrials, which are expected to commence in 2022, for the Group’s lead compound OCT461201, a selective cannabinoid receptor type 2 (“CB2”) agonist with initial indications in the areas of post herpetic neuralgia and visceral pain caused by irritable bowel syndrome.
In December of 2023, the country recently made a new move towards reform that could stimulate the cannabidiol (CBD) industry and provide many patients, such as those with epilepsy , with access to potentially life-changing medical treatments. and Europe to treat severe epilepsy, as well as other medical conditions.
The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinicaltrials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.
While some states have fully legalized medical marijuana, allowing patients with qualifying conditions to access it with a physician’s recommendation, others have more restrictive laws or have not legalized it at all. More rigorous clinicaltrials are needed to establish clear guidelines for its use in MS management.
Harvard Law School is planning to open the first US policy center focused on the legalization and regulation of psychedelics like psilocybin, MDMA, and LSD. . Professor of Law at Harvard Law School. “By Harvard’s new center will be the first to focus solely on psychedelics policy and laws rather than research, though.
Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals. Current Texas Medical Marijuana Regulations CBD laws in Texas are governed by the Compassionate Use Program.
The new law covers the use of MDMA and psilocybin to treat certain conditions. In order to gain access to psychedelics, Australians firsts need to see a psychiatrist. Canada, and Israel are all conducting clinicaltrials on psychedelic treatments. Currently, the U.S., Do you think Sen.
federal law , it has not yet been used in any commonly prescribed medicines. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. federal law.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content